The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The Peterson-KFF Health System Tracker is an online hub monitoring how well the U.S. health system is operating through key quality and cost measures. A partnership of the Peterson Center on Healthcare and KFF, the Tracker documents trends in Health Spending, Quality of Care, Access & Affordability, and Health & Wellbeing through issue briefs and downloadable chart collections. The Tracker also includes the Interactive Health Spending Explorer tool, which helps users analyze more than 50 years of health expenditure data, and a Health System Dashboard, which provides quick and easy access to the latest, most relevant statistics.
KFF and the Peterson Center on Healthcare examine market trends contributing to rising health costs and identify several potential federal and state policy issues to watch throughout 2025, including high-cost drugs, federal funding cuts, and workforce shortages.
This chart collection examines five types of indicators: outcomes of treatment, provision of appropriate treatment, patient safety, preventive services, and health system capacity and workforce shortages. Measuring quality in health care is complex: a vast number of metrics are used to monitor health system performance since there is no singular definition of quality, and data is often limited and delayed.
Promoting price transparency in health care is a policy approach with bi-partisan support in Congress and the public at large. This analysis examines the vast troves of price transparency data that payers are required and finds unlikely prices, inconsistencies, and other oddities that pose major challenges for efforts to use it to promote competition and drive down prices.
This analysis compares 2021 data about deaths in the U.S. and 11 other large, wealthy countries by age and cause to understand the primary drivers of the longevity gap between the U.S. and the comparable countries. It finds that the primary reasons for the gap in 2021 were chronic disease, COVID-19 and substance use disorders.
This analysis finds that Medicare's negotiated prices for 10 high-expenditure prescription drugs are lower than what private Medicare drug plans had been paying, but still much higher than the prices available in 11 other wealthy nations.. It is available on the Peterson-KFF Health System Tracker.
This interactive tool, updated with 2022 data, helps users understand health care costs vary by family size, income, insurance, and health status. Use the dropdown menus to explore scenarios and trends in household health spending.
High cost-sharing and expenses not covered by insurance leave some people with expensive medical bills. But costs are not the only barriers to health care access. According to KFF's new analysis, many adults can face logistical barriers to care, like work schedules or finding a doctor in network or appointment. In 2022, about 1 in 5 adults under age 65 experienced at least one barrier to accessing care aside from cost. The full analysis and…
Recent trends in healthcare utilization and spending suggest that most spending on health services exceeds pre-pandemic levels and health costs are growing at a faster rate than in recent years. However, utilization of care has been uneven by setting and market.
Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations.
Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations, according to a new analysis. The most used drug for people with employer-sponsored health insurance was Jardiance, a drug used to treat diabetes and heart failure, which was taken by more than 911,000 enrollees. The analysis uses the Merative MarketScan 2022 commercial claims to estimate the number of enrollees…
© 2026 KFF